Abstract:In this paper, we explore the utility of resting-state EEG measures as potential biomarkers for the detection and assessment of cognitive decline in mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Neurophysiological biomarkers of AD derived from EEG and FDG-PET, once characterized and validated, would expand the set of existing diagnostic molecular biomarkers of AD pathology with associated biomarkers of disease progression and neural dysfunction. Since symptoms of AD often begin to appear later in life, successful identification of EEG-based biomarkers must account for age-related neurophysiological changes that occur even in healthy individuals. To this end, we collected EEG data from individuals with AD (n = 26), MCI (n = 53), and cognitively normal healthy controls stratified by age into three groups: 18–40 (n = 129), 40–60 (n = 62) and 60–90 (= 55) years old. For each participant, we computed power spectral density at each channel and spectral coherence between pairs of channels. Compared to age matched controls, in the AD group, we found increases in both spectral power and coherence at the slower frequencies (Delta, Theta). A smaller but significant increase in power of slow frequencies was observed for the MCI group, localized to temporal areas. These effects on slow frequency spectral power opposed that of normal aging observed by a decrease in the power of slow frequencies in our control groups. The AD group showed a significant decrease in the spectral power and coherence in the Alpha band consistent with the same effect in normal aging. However, the MCI group did not show any significant change in the Alpha band. Overall, Theta to Alpha ratio (TAR) provided the largest and most significant differences between the AD group and controls. However, differences in the MCI group remained small and localized. We proposed a novel method to quantify these small differences between Theta and Alpha bands’ power using empirically derived distributions of spectral power across the time domain as opposed to averaging power across time. We defined Power Distribution Distance Measure (PDDM) as a distance measure between probability distribution functions (pdf) of Theta and Alpha power. Compared to average TAR, using PDDF enhanced the statistical significance, the effect size, and the spatial distribution of significant effects in the MCI group. We designed classifiers for differentiating individual MCI and AD participants from age-matched controls. The classification performance measured by the area under ROC curve after cross-validation were AUC = 0.85 and AUC = 0.6, for AD and MCI classifiers, respectively. Posterior probability of AD, TAR, and the proposed PDDM measure were all significantly correlated with MMSE score and neuropsychological tests in the AD group.

Quantitative electroencephalography (qEEG), apolipoprotein A-I (APOA-I), and apolipoprotein epsilon 4 (APOE ɛ4) alleles for the diagnosis of mild cognitive impairment and Alzheimer's disease

DECREASED INTRINSIC FUNCTIONAL NETWORK IN COGNITIVELY INTACT ELDERLY APOE-E4 CARRIERS MEASURED BY EIGENVECTOR CENTRALITY MAPPING

IC-P-060: Decreased Intrinsic Functional Network in Cognitively Intact Elderly APOE-E4 Carriers Measured by Eigenvector Centrality Mapping

Decreased Inter-Hemispheric Functional Connectivity in Cognitively Intact Elderly APOE Ɛ4 Carriers: A Preliminary Study

AD Resemblance Atrophy Index of Brain Magnetic Resonance Imaging in Predicting the Progression of Mild Cognitive Impairment Carrying Apolipoprotein E-ε4 Allele

The Role of MRI Biomarkers and Their Interactions with Cognitive Status and APOE Ε4 in Nondemented Elderly Subjects

Apolipoprotein E-Genotyping and MRI Study for Alzheimer’s Disease Classification: PCR-RFLP and Restricted Enzymes AfIII for RS429358 and HaeII for RS7412

Neural Biomarker Diagnosis and Prediction to Mild Cognitive Impairment and Alzheimer’s Disease Using EEG Technology

Disrupted Brain Structural Connectivity: Pathological Interactions Between Genetic APOE ε4 Status and Developed MCI Condition

Associations of apolipoprotein E ε4 allele, regional cerebral blood flow, and serum liver function markers in patients with cognitive impairment

Electroencephalography for Early Detection of Alzheimer’s Disease in Subjective Cognitive Decline

The Significance Of Eeg Alpha Oscillation Spectral Power And Beta Oscillation Phase Synchronization For Diagnosing Probable Alzheimer Disease

APOE Genotype and Age Modifies the Correlation Between Cognitive Status and Metabolites from Hippocampus by a 2D 1H-MRS in Non-Demented Elders

The effect of ApoE ε 4 on clinical and structural MRI markers in prodromal Alzheimer's disease

The Specific Impact of Apolipoprotein E Epsilon 2 on Cognition and Brain Function in Cognitively Normal Elders and Mild Cognitive Impairment Patients

P2-234: Cerebral Blood Flow Velocity Changes in Mild Cognitive Impairment Associated with Apolipoprotein E Ε4 Allele

MRI Markers of Small Vessel Disease and the APOE Allele in Cognitive Impairment

Apolipoprotein E ε4 Specifically Modulates the Hippocampus Functional Connectivity Network in Patients With Amnestic Mild Cognitive Impairment

Resting state EEG biomarkers of cognitive decline associated with Alzheimer’s disease and mild cognitive impairment

Modeling Spatial and Temporal Patterns of APOE ε4 Mediated Glucose Uptake in Mild Cognitive Impairment and Normal Controls

Disrupted Functional and Structural Networks in Cognitively Normal Elderly Subjects with the APOE Ɛ4 Allele.